The total return over the past 12 months is -95.81% vs. +16.94% for the S&P 500. So far it's up -85.60% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (95.81%) | (86.25%) | (78.48%) | (64.00%) | N/A | N/A |
| Total Return CAGR | (95.81%) | (86.25%) | (78.48%) | (64.00%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Moleculin Biotech, Inc. (MBRX)
| Year | Start price | End price | MBRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.31 | $0.48 | (85.60%) | +14.51% | (100.11%) |
| 2025 | $42.50 | $3.31 | (92.21%) | +17.72% | (109.93%) |
| 2024 | $322.00 | $42.50 | (86.80%) | +24.89% | (111.69%) |
| 2023 | $397.50 | $322.00 | (18.99%) | +26.19% | (45.18%) |
| 2022 | $697.50 | $397.50 | (43.01%) | (18.17%) | (24.84%) |
| 2021 | $1,793.50 | $697.50 | (61.11%) | +28.74% | (89.85%) |
| 2020 | $2,058.75 | $1,793.50 | (12.88%) | +18.37% | (31.25%) |
| 2019 | $2,340.00 | $2,058.75 | (12.02%) | +31.22% | (43.24%) |
| 2018 | $4,185.00 | $2,340.00 | (44.09%) | (4.56%) | (39.53%) |
| 2017 | $5,130.00 | $4,185.00 | (18.42%) | +21.70% | (40.12%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
